뇌졸중 관리 시장 보고서 : 유형, 용도, 최종사용자, 지역별(2024-2032년)

The global stroke management market size reached US$ 35.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 61.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032. The rising burden of strokes on healthcare systems, the increasing focus on patient-centered care and personalized treatment plans, and the growing research and development efforts to improve stroke management techniques and develop new therapies are some of the factors propelling the market.

Stroke management involves a comprehensive approach to reduce the impact and long-term consequences of stroke, a medical emergency caused by disrupted blood flow to the brain. Effective stroke management is crucial to minimize brain damage, improve patient outcomes, and enhance quality of life. Prompt and accurate diagnosis is essential in stroke management. Quick assessment tools, such as the FAST acronym (Facial drooping, Arm weakness, Speech difficulties, Time to call emergency services), aid in identifying stroke symptoms and enabling timely medical intervention. Diagnostic imaging, such as computed tomography (CT) scans or magnetic resonance imaging (MRI), helps determine the type and location of the stroke. Immediate treatment focuses on restoring blood flow to the brain. Clot-dissolving medications like tissue plasminogen activator (tPA) or mechanical thrombectomy may be used for ischemic stroke. Hemorrhagic stroke may require surgical interventions to stop bleeding and relieve pressure on the brain. Post-stroke management involves rehabilitation to restore lost functions and prevent disability. This may include physical therapy, occupational therapy, speech therapy, and psychological support. Medications to manage risk factors like high blood pressure, high cholesterol, and blood thinners may also be prescribed. Additionally, preventive measures are essential to reduce the risk of recurrent strokes. Lifestyle modifications such as a healthy diet, regular exercise, smoking cessation, and managing chronic conditions, such as diabetes or atrial fibrillation, are crucial to stroke management. Ongoing research and advancements in stroke treatment and rehabilitation continue to improve stroke management strategies and outcomes.

The global market is primarily driven by the growing incidence of strokes. In line with this, the increasing aging population is significantly contributing to the market. Furthermore, the rising technological advancements in diagnostics, imaging, and treatment options are positively influencing the market. The growing public awareness about the signs, symptoms, and importance of prompt stroke management is also catalyzing the market. Moreover, the government's campaigns and initiatives to address stroke prevention and management promote market expansion. Besides, the favorable reimbursement policies for stroke management procedures and treatments incentivize healthcare providers and propel the market. Additionally, the rapid adoption of telemedicine and remote monitoring technologies allows for remote stroke management and expands the market reach. The establishment of dedicated stroke centers and specialized facilities enhances stroke management capabilities and strengthens the market.

Stroke Management Market Trends/Drivers:

Increasing prevalence of chronic diseases

The rising prevalence of chronic diseases is fostering the market. Chronic diseases, such as cardiovascular diseases, diabetes, and hypertension, are major stroke risk factors. As the global population ages and lifestyles become more sedentary, the prevalence of these chronic conditions continues to increase. This results in a larger population at risk of experiencing strokes. The increasing prevalence of chronic diseases creates a greater demand for effective stroke management strategies. Healthcare providers and organizations are prompted to develop comprehensive stroke prevention programs and implement timely and efficient treatment protocols. Additionally, there is a growing need for ongoing monitoring and management of chronic conditions to minimize the risk of stroke occurrence or recurrence. Public health initiatives, education campaigns, and preventive measures are being implemented to raise awareness about the relationship between chronic diseases and strokes. These efforts aim to promote early detection, lifestyle modifications, and adherence to treatment regimens, ultimately reducing the burden of strokes and fueling the market for stroke management solutions.

Rising awareness among individuals regarding the benefits of early diagnosis and treatments

Rising awareness among individuals about the benefits of early diagnosis and treatments is creating a positive outlook for the market. As public knowledge about the signs, symptoms, and consequences of strokes improves, individuals are becoming more proactive in seeking timely medical attention. Increased awareness empowers individuals to recognize stroke symptoms promptly and understand the importance of seeking immediate medical help. Recognizing symptoms such as sudden numbness or weakness, difficulty speaking or understanding, and severe headache prompts individuals to seek emergency care without delay. Early diagnosis and prompt treatment are critical in minimizing the impact of strokes and improving patient outcomes. With greater awareness, individuals are more likely to act swiftly, leading to faster intervention and potentially life-saving treatments such as clot-dissolving medications or mechanical thrombectomy. Efforts to raise awareness include public health campaigns, educational initiatives, and community outreach programs. These endeavors aim to educate individuals about stroke prevention, risk factors, and the need for immediate medical intervention. By increasing awareness, individuals are empowered to take proactive measures, bolstering the market for stroke management solutions and improving overall stroke care.

Introduction of new and advanced devices and drugs

Introducing new and advanced devices and drugs offers numerous opportunities for the market. Technological advancements and continuous innovation in medical devices and pharmaceuticals have revolutionized stroke care, improving patient outcomes and catalyzing the market. New devices, such as advanced imaging, neuro-interventional, and robotic-assisted systems, have enhanced the accuracy and precision of stroke diagnosis and treatment. These devices enable healthcare providers to swiftly and effectively remove clots, restore blood flow to the brain, and minimize the extent of brain damage. Additionally, innovative rehabilitation devices and assistive technologies aid in stroke recovery and rehabilitation. The development of new drugs and pharmaceutical interventions has also played a vital role in driving the market. Thrombolytic drugs, neuroprotective agents, and antiplatelet medications have significantly improved stroke treatment and prevention. These drugs aim to dissolve clots, protect brain cells, and manage risk factors to reduce the likelihood of recurrent strokes. Moreover, introducing new devices and drugs has led to a paradigm shift in stroke management, enabling more precise diagnoses, minimally invasive treatments, and targeted therapies. These advancements enhance patient care and create new opportunities for healthcare providers and manufacturers, propelling the market.

Stroke Management Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global stroke management market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, application and end user.

Breakup by Type:

Diagnostics

Computed Tomography Scan (CT Scan)

Magnetic Resonance Imaging (MRI)

Carotid Ultrasound

Cerebral Angiography

Electrocardiography

Echocardiography

Others

Therapeutics

Tissue Plasminogen Activator

Anticoagulant

Antiplatelet

Antihypertensive

Diagnostics dominate the market

The report has provided a detailed breakup and analysis of the market based on the type. This includes diagnostics (computed tomography scan (CT Scan), magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, others) and therapeutics (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive). According to the report, diagnostics represented the largest segment.

Diagnostics are crucial in accurately identifying and assessing strokes, enabling timely and effective treatment decisions. CT scans and MRIs are key diagnostic tools used to evaluate stroke patients. CT scans provide rapid imaging to detect bleeding or blockages in blood vessels, helping determine the type and location of the stroke. MRIs, on the other hand, offer detailed brain imaging, assisting in identifying ischemic areas and aiding in treatment planning. The increasing prevalence of strokes and the emphasis on early detection and intervention drive the demand for diagnostic tools, such as CT scans and MRIs.

Technological advancements in CT and MRI imaging, such as higher resolution, faster scanning times, and improved imaging protocols, have enhanced the accuracy and efficiency of stroke diagnosis. The diagnostics segment's growth is further fuelled by integrating artificial intelligence (AI) algorithms into imaging systems, enabling automated analysis and interpretation of imaging data. This streamlines the diagnostic process, expedites treatment decisions, and improves patient outcomes.

Breakup by Application:

Ischemic Stroke

Haemorrhagic Stroke

Others

Ischemic Stroke holds the largest share of the market

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes ischemic stroke, haemorrhagic stroke, and others. According to the report, ischemic stroke accounted for the largest market share.

Ischemic stroke is the most common type, caused by the blockage or narrowing of blood vessels supplying the brain, leading to reduced blood flow and oxygen delivery. The focus on ischemic stroke management drives themarket growth as it accounts for a substantial portion of stroke cases. The increasing incidence of ischemic stroke, often associated with risk factors like hypertension, diabetes, and a sedentary lifestyle, demands effective management strategies.

Advancements in ischemic stroke management, such as the development of thrombolytic drugs like tissue plasminogen activator (tPA) and mechanical thrombectomy procedures, have revolutionized treatment options. These interventions aim to restore blood flow to the affected area, minimize brain damage, and improve patient outcomes. The emphasis on ischemic stroke management is further supported by public health initiatives promoting stroke prevention, early recognition of symptoms, and rapid intervention. These initiatives propel the market by increasing awareness, encouraging individuals to seek medical help promptly, and implementing evidence-based management approaches.

Breakup by End User:

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Others

Hospitals holds the largest share of the market

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, ambulatory surgical centers, diagnostic centers, and others. According to the report, hospitals accounted for the largest market share.

Hospitals play a critical role in stroke care, as they are the primary healthcare facilities for acute stroke treatment, specialized diagnostics, and rehabilitation services. The demand for stroke management solutions is propelled by hospitals' need to provide patients with comprehensive and specialized stroke care. As the burden of strokes rises, hospitals strive to enhance their capabilities in stroke diagnosis, treatment, and rehabilitation, impacting the market positively.

Hospitals invest in advanced imaging systems, neuro-interventional devices, and rehabilitation technologies to deliver optimal stroke care. They collaborate with stroke management companies and engage in clinical research to implement evidence-based practices and offer the latest treatment options. Furthermore, hospitals serve as centers for stroke education and training, disseminating knowledge to healthcare professionals regarding stroke prevention, early recognition, and appropriate management. This contributes to improved patient outcomes and raises awareness among the healthcare community, propelling the market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

North America is a key market for stroke management due to several factors contributing to its growth and development. The region has a high prevalence of stroke cases, making it a significant market for stroke management solutions. The region's aging population, sedentary lifestyles, and high incidence of risk factors such as hypertension and obesity contribute to the increased burden of strokes. Furthermore, the region boasts advanced healthcare infrastructure and robust research and development capabilities. This enables the region to lead in developing and adopting innovative stroke management technologies, diagnostic tools, and treatment modalities.

Moreover, North America has a well-established healthcare system and reimbursement structure that supports the adoption of stroke management solutions. Favorable reimbursement policies and insurance coverage for stroke-related interventions and treatments drive the market. The presence of leading stroke management companies, healthcare providers, and research institutions in North America fosters collaboration, research, and advancements in stroke management practices. This contributes to the market growth by continually improving treatment outcomes and driving the adoption of new technologies and techniques.

Competitive Landscape:

Top stroke management companies are strengthening the market through their expertise, innovation, and commitment to improving patient outcomes. These companies invest heavily in research and development to develop cutting-edge technologies, devices, and pharmaceuticals for effective stroke prevention, diagnosis, treatment, and rehabilitation. Leading stroke management companies actively collaborate with healthcare providers, research institutions, and industry experts to drive innovation and stay at the forefront of stroke care. They conduct clinical trials and studies to gather evidence-based data and continuously improve their products and services. These companies are also crucial in raising awareness about stroke prevention and early intervention. They engage in educational initiatives, public health campaigns, and partnerships with patient advocacy groups to promote stroke awareness and provide resources to healthcare professionals and the general public. Moreover, top stroke management companies focus on delivering comprehensive solutions that encompass diagnostics, acute care, rehabilitation, and ongoing management. By offering integrated and patient-centric approaches, they strive to optimize patient outcomes and improve quality of life through their commitment to advancing stroke management practices.

The report has provided a comprehensive analysis of the competitive landscape in the stroke management market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

B. Braun Melsungen AG

Boston Scientific Corporation

Bristol-Myers Squibb Company

Cardinal Health

General Electric Company

GlaxoSmithKline plc

Medtronic plc

Merck & Co. Inc.

Siemens Healthineers AG (Siemens AG).

Recent Developments:

In 2019, Abbott launched the Alinity m diagnostics system, a compact molecular testing platform designed to deliver fast and accurate results for infectious diseases like HIV, hepatitis, and more.

In 2019, B. Braun announced a collaboration with GuardRFID Solutions to enhance the company's asset tracking and management capabilities, improving efficiency in healthcare environments.

In 2019, Boston Scientific received FDA approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, a minimally invasive implantable device for reducing the risk of stroke in patients with non-valvular atrial fibrillation.

Key Questions Answered in This Report:

• How has the global stroke management market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global stroke management market?
• What is the impact of each driver, restraint, and opportunity on the global stroke management market?
• What are the key regional markets?
• Which countries represent the most attractive stroke management market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the global stroke management market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the global stroke management market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the global stroke management market?
• What is the competitive structure of the global stroke management market?
• Who are the key players/companies in the global stroke management market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Stroke Management Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Diagnostics
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Computed Tomography Scan (CT Scan)
    • 6.1.2.2 Magnetic Resonance Imaging (MRI)
    • 6.1.2.3 Carotid Ultrasound
    • 6.1.2.4 Cerebral Angiography
    • 6.1.2.5 Electrocardiography
    • 6.1.2.6 Echocardiography
    • 6.1.2.7 Others
  • 6.1.3 Market Forecast
• 6.2 Therapeutics
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Tissue Plasminogen Activator
    • 6.2.2.2 Anticoagulant
    • 6.2.2.3 Antiplatelet
    • 6.2.2.4 Antihypertensive
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Ischemic Stroke
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Haemorrhagic Stroke
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Surgical Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Diagnostic Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 B. Braun Melsungen AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Boston Scientific Corporation
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Bristol-Myers Squibb Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Cardinal Health
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 General Electric Company
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 GlaxoSmithKline plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Medtronic plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Merck & Co. Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Siemens Healthineers AG (Siemens AG)
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis